Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials

PD Coxeter, PJ Schluter, HL Eastwood, CJ Nikles, PP Glasziou

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)

Abstract

Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57%) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96%) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100%) participants' response to 'total sleep time' and for 23 (96%) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95% CI 0.23, 0.47) to 0.55 (95% CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)215-222
Number of pages8
JournalComplementary Therapies in Medicine
Volume11
Issue number4
DOIs
Publication statusPublished - Dec 2003
Externally publishedYes

Cite this

@article{6fa3d95739eb42d2995473f6a6c4d0cd,
title = "Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials",
abstract = "Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57{\%}) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96{\%}) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100{\%}) participants' response to 'total sleep time' and for 23 (96{\%}) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95{\%} CI 0.23, 0.47) to 0.55 (95{\%} CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.",
author = "PD Coxeter and PJ Schluter and HL Eastwood and CJ Nikles and PP Glasziou",
year = "2003",
month = "12",
doi = "10.1016/S0965-2299(03)00122-5",
language = "English",
volume = "11",
pages = "215--222",
journal = "Complementary Medical Research",
issn = "0965-2299",
publisher = "Churchill Livingstone",
number = "4",

}

Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials. / Coxeter, PD; Schluter, PJ; Eastwood, HL; Nikles, CJ; Glasziou, PP.

In: Complementary Therapies in Medicine, Vol. 11, No. 4, 12.2003, p. 215-222.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials

AU - Coxeter, PD

AU - Schluter, PJ

AU - Eastwood, HL

AU - Nikles, CJ

AU - Glasziou, PP

PY - 2003/12

Y1 - 2003/12

N2 - Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57%) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96%) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100%) participants' response to 'total sleep time' and for 23 (96%) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95% CI 0.23, 0.47) to 0.55 (95% CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.

AB - Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57%) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96%) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100%) participants' response to 'total sleep time' and for 23 (96%) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95% CI 0.23, 0.47) to 0.55 (95% CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.

U2 - 10.1016/S0965-2299(03)00122-5

DO - 10.1016/S0965-2299(03)00122-5

M3 - Article

VL - 11

SP - 215

EP - 222

JO - Complementary Medical Research

JF - Complementary Medical Research

SN - 0965-2299

IS - 4

ER -